Compare RUBI & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUBI | CMND |
|---|---|---|
| Founded | N/A | 2017 |
| Country | Marshall Islands | Canada |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 2.9M |
| IPO Year | N/A | N/A |
| Metric | RUBI | CMND |
|---|---|---|
| Price | $0.86 | $2.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 797.2K | 138.0K |
| Earning Date | 05-06-2020 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,139,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.39 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.77 | $1.74 |
| 52 Week High | $200.70 | $61.60 |
| Indicator | RUBI | CMND |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 60.76 |
| Support Level | N/A | $2.12 |
| Resistance Level | N/A | $2.69 |
| Average True Range (ATR) | 0.00 | 0.29 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 0.00 | 81.00 |
Rubico Inc operates as a holding company. It is an eco-conscious international crude oil shipping company. The company's primary business is the ownership and operation of an eco-conscious fleet of tanker vessels designed for enhanced fuel efficiency, reduced greenhouse emissions, and a wide range of environmentally friendly technologies.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.